Prostate cancer. Primary hormonal treatment.
BACKGROUND
No other treatment matches the 40-60% objective response and up to 80% subjective responses for primary hormonal therapy in patients with symptomatic disease. This makes primary hormonal treatment first-line therapy metastatic prostate cancer.


RESULTS
The treatment outcome is determined by the initial and intermittent prognostic factors. In the multihormonal environment, several endocrine treatments have shown competing levels of response. Maximal androgen blockade has emerged as the best treatment to achieve a response and even has increased survival modestly. Monotherapy with nonsteroidal antiandrogens plays a role in patients trying to preserve their potency.


CONCLUSIONS
Pilot treatment adjusted to the medical needs and social preferences of the patient is appropriate and allows a tailored approach to the individual patient.
Denis
L
L
Department of Urology, A. Z. Middelheim, Antwerp, Belgium.
D003131:Combined Modality Therapy; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use; D013196:Dihydrotestosterone / Q000378:metabolism; D004967:Estrogens / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D009919:Orchiectomy; D010358:Patient Participation; D011467:Prostate / Q000254:growth & development / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000628:therapy*; D011944:Receptors, Androgen / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism
D004967:Estrogens; D011944:Receptors, Androgen; D013196:Dihydrotestosterone; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D017373:Cyproterone Acetate; D004054:Diethylstilbestrol; D005485:Flutamide; D007986:Luteinizing Hormone